Clinical Trial Update: A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 biomarker study evaluating standard-of-care Radium-223 chloride in metastatic castration-resistant prostate cancer; study completed with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Radium-223-chloride

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-09-29